INT213903

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 10
Disease Relevance 5.03
Pain Relevance 0.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoplasm (EGFR, ERBB2) cell proliferation (EGFR, ERBB2) signal transduction (EGFR, ERBB2)
plasma membrane (EGFR, ERBB2) nucleus (EGFR, ERBB2) endosome (EGFR)
EGFR (Homo sapiens)
ERBB2 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 4 76.08 Quite High
abdominal pain 1 24.88 Low Low
Pain 6 22.32 Low Low
cva 4 18.80 Low Low
Central nervous system 22 5.00 Very Low Very Low Very Low
headache 9 5.00 Very Low Very Low Very Low
imagery 6 5.00 Very Low Very Low Very Low
palliative 5 5.00 Very Low Very Low Very Low
antagonist 3 5.00 Very Low Very Low Very Low
pruritus 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Breast Cancer 314 98.64 Very High Very High Very High
Cancer 286 94.92 High High
Solid Tumor 21 93.96 High High
Colon Cancer 4 93.56 High High
Disease 178 89.40 High High
Apoptosis 60 88.24 High High
Adhesions 3 87.16 High High
Advanced Or Metastatic Breast Cancer 121 86.68 High High
Toxicity 47 86.48 High High
Anaplastic Astrocytoma 28 83.60 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Subsequently, dimerization of activated EGFR with other HER family receptors, particularly HER2, activates intracellular signaling pathways, which in turn may enhance nuclear ER signaling [4], thus completing a vicious cycle of events.
EGFR Binding (dimerization) of HER2
1) Confidence 0.37 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001220 Disease Relevance 0.30 Pain Relevance 0.04
It has been suggested that c-erbB2 is a preferred partner for heterodimerization with the other members of the EGFR family.
EGFR Binding (heterodimerization) of c-erbB2
2) Confidence 0.36 Published 2010 Journal Diagn Pathol Section Body Doc Link PMC2859381 Disease Relevance 0.95 Pain Relevance 0
against both EGFR and HER-2/neu, which shows improved clinical efficacy and has
EGFR Binding (neu) of HER-2
3) Confidence 0.36 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.51 Pain Relevance 0
that the treatment outcome may depend on the expression and responsiveness of the heterodimerization of HER-2 with EGFR.
EGFR Binding (heterodimerization) of HER-2
4) Confidence 0.34 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.50 Pain Relevance 0
HER2 assumes an open conformation, with its dimerization domain permanently exposed for interaction with other ligand-activated HER receptors (9).
HER Binding (interaction) of HER2
5) Confidence 0.34 Published 2009 Journal Japanese Journal of Clinical Oncology Section Body Doc Link PMC2661001 Disease Relevance 0.34 Pain Relevance 0
ErbB2, whilst having no exogenous ligand, is the preferred partner for heterodimerization with ErbB1, ErbB3 and ErbB4 as it amplifies the mitogenic signal with potent growth and survival effects.
ErbB1 Binding (heterodimerization) of ErbB2
6) Confidence 0.33 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.27 Pain Relevance 0
The data clearly demonstrate that the interaction between HER2 and EGFR is not sufficiently addressed in targeted and combination breast cancer therapies [2] and should be studied extensively.
EGFR Binding (interaction) of HER2 associated with breast cancer
7) Confidence 0.21 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575526 Disease Relevance 0.44 Pain Relevance 0
It is of importance that heterodimers of EGFR and Her2 have higher stability and therefore cause prolonged receptor signaling compared with EGFR homodimers, a fact that serves as rationale for dual targeting of EGFR and Her2 (Konecny et al 2006; Xia et al 2006).
EGFR Binding (heterodimers) of Her2
8) Confidence 0.18 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721347 Disease Relevance 0.48 Pain Relevance 0
As described, a powerful interaction between Her2 and EGFR exists.
EGFR Binding (interaction) of Her2
9) Confidence 0.18 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721347 Disease Relevance 0.64 Pain Relevance 0
Pertuzumab is a monoclonal antibody that inhibits dimerization of ERBB2 with EGFR, ERBB3, and ERBB4.
EGFR Binding (dimerization) of ERBB2
10) Confidence 0.12 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2814233 Disease Relevance 0.60 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox